Core Viewpoint - Meihua Medical (301363) has shown a positive stock performance with a closing price of 34.88 yuan, reflecting a 6.57% increase as of February 13, 2026, with significant trading volume and capital inflow [1] Financial Performance - For the first three quarters of 2025, Meihua Medical reported a main revenue of 1.194 billion yuan, a year-on-year increase of 3.28%, while the net profit attributable to shareholders decreased by 19.25% to 208 million yuan [3] - In Q3 2025, the company achieved a single-quarter main revenue of 462 million yuan, up 2.56% year-on-year, and a net profit of 93.9 million yuan, reflecting a 5.89% increase year-on-year [3] - The company's gross profit margin stands at 39.34%, with a debt ratio of 11.43% and investment income of 4.9031 million yuan [3] Capital Flow - On February 13, 2026, the net inflow of main funds was 113 million yuan, accounting for 13.19% of the total transaction amount, while retail investors experienced a net outflow of 150 million yuan, representing 17.47% of the total transaction amount [1] - The financing data indicates a net purchase of 12.9942 million yuan on the same day, with a total financing balance of 276 million yuan [2] Institutional Ratings - In the last 90 days, four institutions have rated Meihua Medical with a "buy" recommendation, and the average target price set by these institutions is 24.57 yuan [4]
美好医疗（301363）2月13日主力资金净买入1.13亿元